143 related articles for article (PubMed ID: 24616582)
21. Inhibition of orthotopic human bladder tumor growth by lentiviral gene transfer of endostatin.
Kikuchi E; Menendez S; Ohori M; Cordon-Cardo C; Kasahara N; Bochner BH
Clin Cancer Res; 2004 Mar; 10(5):1835-42. PubMed ID: 15014038
[TBL] [Abstract][Full Text] [Related]
22. [Characterization of a novel transplantable orthotopic nude mouse model with xenografted human bladder transitional cell tumor (BIU-87)].
Li C; Yan RP; Yuan GH; Feng YG; Wang JS; Gao X; Huang YS; Zhou JB; Xie SS
Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):733-6. PubMed ID: 17366782
[TBL] [Abstract][Full Text] [Related]
23. In vivo evaluation of mucoadhesive nanoparticulate docetaxel for intravesical treatment of non-muscle-invasive bladder cancer.
Mugabe C; Matsui Y; So AI; Gleave ME; Baker JH; Minchinton AI; Manisali I; Liggins R; Brooks DE; Burt HM
Clin Cancer Res; 2011 May; 17(9):2788-98. PubMed ID: 21357680
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of an orthotopic rat bladder urothelial cell carcinoma model by cystoscopy.
Hendricksen K; Molkenboer-Kuenen J; Oosterwijk E; Hulsbergen-van de Kaa CA; Witjes JA
BJU Int; 2008 Apr; 101(7):889-93. PubMed ID: 18201266
[TBL] [Abstract][Full Text] [Related]
25. Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin.
Hadaschik BA; Adomat H; Fazli L; Fradet Y; Andersen RJ; Gleave ME; So AI
Clin Cancer Res; 2008 Mar; 14(5):1510-8. PubMed ID: 18316576
[TBL] [Abstract][Full Text] [Related]
26. [Establishment of a human bladder cancer cell line stably co-expressing hSPRY2 and luciferase genes and its subcutaneous tumor xenograft model in nude mice].
Yin X; Li F; Jin Y; Yin Z; Qi S; Wu S; Wang Z; Wang L; Yu J; Gao J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Mar; 33(3):337-341. PubMed ID: 28274312
[TBL] [Abstract][Full Text] [Related]
27. Inactivation of p53 and Pten promotes invasive bladder cancer.
Puzio-Kuter AM; Castillo-Martin M; Kinkade CW; Wang X; Shen TH; Matos T; Shen MM; Cordon-Cardo C; Abate-Shen C
Genes Dev; 2009 Mar; 23(6):675-80. PubMed ID: 19261747
[TBL] [Abstract][Full Text] [Related]
28. [Establishment and application of an orthotopic murine bladder cancer model].
Yang SM; Wen DG; Hou JQ; He J; Cen JN; Chen JH
Ai Zheng; 2007 Apr; 26(4):341-5. PubMed ID: 17430648
[TBL] [Abstract][Full Text] [Related]
29. A Non-invasive Imageable GFP-expressing Mouse Model of Orthotopic Human Bladder Cancer.
Sun YU; Nishino H; Zhao M; Miyake K; Sugisawa N; Yamamoto J; Tashiro Y; Inubushi S; Hamada K; Zhu G; Lim H; Hoffman RM
In Vivo; 2020; 34(6):3225-3231. PubMed ID: 33144427
[TBL] [Abstract][Full Text] [Related]
30. Minimally invasive establishment of murine orthotopic bladder xenografts.
Jäger W; Moskalev I; Janssen C; Hayashi T; Gust KM; Awrey S; Black PC
J Vis Exp; 2014 Feb; (84):e51123. PubMed ID: 24561487
[TBL] [Abstract][Full Text] [Related]
31. Validating bladder cancer xenograft bioluminescence with magnetic resonance imaging: the significance of hypoxia and necrosis.
Black PC; Shetty A; Brown GA; Esparza-Coss E; Metwalli AR; Agarwal PK; McConkey DJ; Hazle JD; Dinney CP
BJU Int; 2010 Dec; 106(11):1799-804. PubMed ID: 20500508
[TBL] [Abstract][Full Text] [Related]
32. Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.
Pfost B; Seidl C; Autenrieth M; Saur D; Bruchertseifer F; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
J Nucl Med; 2009 Oct; 50(10):1700-8. PubMed ID: 19793735
[TBL] [Abstract][Full Text] [Related]
33. Differential mTOR pathway profiles in bladder cancer cell line subtypes to predict sensitivity to mTOR inhibition.
Hau AM; Nakasaki M; Nakashima K; Krish G; Hansel DE
Urol Oncol; 2017 Oct; 35(10):593-599. PubMed ID: 28427860
[TBL] [Abstract][Full Text] [Related]
34. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
35. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
[TBL] [Abstract][Full Text] [Related]
36. Targeting mTOR and p53 Signaling Inhibits Muscle Invasive Bladder Cancer In Vivo.
Madka V; Mohammed A; Li Q; Zhang Y; Biddick L; Patlolla JM; Lightfoot S; Towner RA; Wu XR; Steele VE; Kopelovich L; Rao CV
Cancer Prev Res (Phila); 2016 Jan; 9(1):53-62. PubMed ID: 26577454
[TBL] [Abstract][Full Text] [Related]
37. Establishment of a bioluminescent Renca cell line for renal carcinoma research.
Ding J; Wang C; Chang X
Int Urol Nephrol; 2018 Jan; 50(1):55-61. PubMed ID: 28975469
[TBL] [Abstract][Full Text] [Related]
38. miR-190b promotes tumor growth and metastasis via suppressing NLRC3 in bladder carcinoma.
Chen Z; Yang L; Chen L; Li J; Zhang F; Xing Y; Zhao J
FASEB J; 2020 Mar; 34(3):4072-4084. PubMed ID: 31953872
[TBL] [Abstract][Full Text] [Related]
39. An orthotopic bladder tumor model and the evaluation of intravesical saRNA treatment.
Kang MR; Yang G; Charisse K; Epstein-Barash H; Manoharan M; Li LC
J Vis Exp; 2012 Jul; (65):. PubMed ID: 22872227
[TBL] [Abstract][Full Text] [Related]
40. Optimizing live-animal bioluminescence imaging prediction of tumor burden in human prostate cancer xenograft models in SCID-NSG mice.
Kim S; Zhang Y; Tang S; Qin C; Karelia D; Sharma A; Jiang C; Lu J
Prostate; 2019 Jun; 79(9):949-960. PubMed ID: 30958914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
